AGEN · LGND 10-KFeb 27 '26
“In May 2024, we entered into the Agenus Agreement to support BOT/BAL clinical development.”
AMGN · LGND 10-KFeb 27 '26
“Our royalty portfolio includes products marketed by leading biopharmaceutical companies such as Amgen, Merck, Jazz, Recordati, and Sanofi.”